News
Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.
EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ --...
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ --...
EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ --...
Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ --...
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, RI, April 27, 2021 /PRNewswire/ --...
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)
PROVIDENCE, RI, February 17, 2021 /PRNewswire/...
EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19
PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ --...
EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program
PROVIDENCE, R.I., Dec. 29,...
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)
PROVIDENCE, RI, December 15, 2020 /PRNewswire/...
FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities
PROVIDENCE, RI, October 22, 2020 /PRNewswire/ --...
EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics
PROVIDENCE, RI, August 24, 2020 /PRNewswire/ --...
Six months in, are we any closer to a vaccine?
Are we "Checking the Box" or Making Vaccines...